The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Medicinal Cannabis—Potential Drug Interactions
Open accessAbstract
The endocannabinoids system (ECS) has garnered considerable interest as a potential therapeutic target in various carcinomas and cancer-related conditions alongside neurodegenerative diseases. Cannabinoids are implemented in several physiological processes such as appetite stimulation, energy balance, pain modulation and the control of chemotherapy-induced nausea and vomiting (CINV). However, pharmacokinetics and pharmacodynamics interactions could be perceived in drug combinations, so in this short review we tried to shed light on the potential drug interactions of medicinal cannabis. Hitherto, few data have been provided to the healthcare practitioners about the drug–drug interactions of cannabinoids with other prescription medications. In general, cannabinoids are usually well tolerated, but bidirectional effects may be expected with concomitant administered agents via affected membrane transporters (Glycoprotein p, breast cancer resistance proteins, and multidrug resistance proteins) and metabolizing enzymes (Cytochrome P450 and UDP-glucuronosyltransferases). Caution should be undertaken to closely monitor the responses of cannabis users with certain drugs to guard their safety, especially for the elderly and people with chronic diseases or kidney and liver conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“The phytocannabinoids have been shown to have a range of biological activities by mimicking the endocannabinoids, for example, anandamide and 2-arachidonoylglycerol act as the endogenous ligand of cannabinoid receptors CB1 and CB2 [5–7].”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Portenoy, R. K., Ganae-Motan, E. D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., & Fallon, M. T. (2012) · The Journal of Pain · doi:10.1016/j.jpain.2012.01.003 · Cited by 420
Cannabinoid–Opioid Interaction in Chronic Pain
Abrams, D. I., Couey, P., Shade, S. B., Kelly, M. E., & Benowitz, N. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.188 · Cited by 319
Lynch, M. E., Cesar-Rittenberg, P., & Hohmann, A. G. (2014) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.02.018 · Cited by 266
Haroutounian, S., Ratz, Y., Ginosar, Y., Furmanov, K., Saifi, F., Meidan, R., & Davidson, E. (2016) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000364 · Cited by 234
Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H.-M., & Baranowski, V. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x167525 · Cited by 214
Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Zhu, H.-J., Wang, J.-S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., & DeVane, C. L. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098541 · Cited by 192
Cited by
Phytocannabinoids: Origins and Biosynthesis
Gülck, T., & Møller, B. L. (2020) · Trends in Plant Science · doi:10.1016/j.tplants.2020.05.005 · Cited by 392
Page, R. L., Allen, L. A., Kloner, R. A., Carriker, C. R., Martel, C., Morris, A. A., Piano, M. R., Rana, J. S., Saucedo, J. F., & On behalf of the American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research (2020) · Circulation · doi:10.1161/cir.0000000000000883 · Cited by 260
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78
“A comprehensive overview of the pharmacokinetic interactions of cannabinoids has been reported by Alsherbiny and Li 114 Pharmacodynamic interactions also need to be considered with CBM, particularly THC, administration.”
Background“Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations
MacCallum, C. A., Lo, L. A., & Boivin, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.002 · Cited by 71
Smiley, C. E., Saleh, H. K., Nimchuk, K. E., Garcia-Keller, C., & Gass, J. T. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113517 · Cited by 15
Metadata
- Authors
- Alsherbiny, M. A., & Li, C. G.
- Venue
- Medicines
- Publisher
- MDPI AG
- Published
- 2018-12-23
- Volume
- 6
- Issue
- 1
- Pages
- 3
- ISSN
- 2305-6320 (ISSN-L)
- OpenAlex
- W2903524840
- Cited by
- 163
- References
- 12
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medicinal Cannabis—Potential Drug Interactions. https://app.cochat.ai/papers/10.3390/medicines6010003
- The paper
- Alsherbiny, M. A., & Li, C. G. (2018). Medicinal Cannabis—Potential Drug Interactions. Medicines. https://doi.org/10.3390/medicines6010003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.